Pediatric Hematology and Oncology, 23:1–7, 2006Copyright C Taylor & Francis Group, LLCISSN: 0888-0018 print / 1521-0669 onlineDOI: 10.1080/08880010600803214
CONCURRENT DEVELOPMENT OF CROHN DISEASE AND MYELODYSPLASTIC SYNDROME IN A CHILD: Case Report and Literature Review Sergio Carlos Nahas, Caio Sergio Rizkallah Nahas, and Carlos Frederico Marques ✷ Colon and Rectum Surgery Department, Hospitaldas Cl´ınicas, Medical School, University of S˜ao Paulo, S˜ao Paulo, BrazilMarcello Rodriguez Borba ✷ Surgery Department of University Hospital, Universityof S˜ao Paulo, S˜ao Paulo, BrazilAlfredo Salim Helito ✷ Hospital S´ırio-L´ıbanˆes of S˜ao Paulo, S˜ao Paulo, BrazilVicente Odoni ✷ Pediatric Department of Hospital das Cl´ınicas, Medical School,University of S˜ao Paulo, S˜ao Paulo, Brazil✷ A small number of cases of Crohn disease associated with myelodysplastic syndromes or leukemiahave been reported in adults in the last 25 years in the English-language medical literature. Theauthors report a case of a 9-year-old boy who developed Crohn disease and myelodysplastic syndromeconcurrently. Analysis of his bone marrow showed a chromosome 20 abnormality. Although chro-mosome 20 abnormalities have been reported in a minority of these patients, the significance of thisassociation remains unclear at the present time.Keywords
Crohn diseas, leukemia, myelodysplastic syndromes, pancytopenia
An association between Crohn disease (CD) and myelodysplastic syn-
dromes (MDS) or leukemia has been suggested on the basis of concomitant
findings of these disorders in a total of 24 cases reported in the English-
language medical literature [1–11]. Interestingly, all patients reported were
adults (mean age of 68 years old, range 28–83). Eng et al. , the first to
report such a condition in 4 patients, found clonal abnormalities of chromo-
some 20 in 3 cases. Although the association of chromosome 20 abnormalities
and MDS has been described , whether such abnormalities account for
the association between MDS and CD is unknown. Moreover, since Eng’s
Received 30 January 2006; accepted 12 May 2006. Address correspondence to Dr. Sergio Carlos Nahas, Rua Adma Jafet 50, conj 131/132, Bela Vista,
01308 050 S˜ao Paulo, SP, Brazil. E-mail: [email protected]
publication, all subsequent reports have failed to demonstrate chromosome
20 abnormalities in patients with CD and MDS [2–11].
Herein, we report a case of concurrent development of CD and MDS in
a child with a chromosome 20 abnormality. CASE REPORT
A 9-year-old boy presented with a 1-week history of high fever (39–40◦C)
associated with a 1-month history of anorexia, nausea, and intermittent dif-
fuse colicky abdominal pain. He had experienced episodes of diarrhea and
a 10% weight loss over the last month. On physical examination a right
lower quadrant tender mass was palpable. Laboratory data revealed normo-
cytic anemia (hemoglobin level, 85 g/L; mean corpuscular volume, 89 u3),
leukopenia (leukocyte count, 2.6 × 109/L), and thrombocytopenia (platelet 39count, 110 × 109/L). Reticulocyte count was 1.6%. Erythrocyte sedimenta- 40tion rate was 90 mm/h. He had negative serology for infectious diseases,
negative stool cultures, and normal rheumatologic markers.
A colonoscopy was performed because of a clinical suspicion for inflam-
matory bowel disease and revealed segmental aphthous ulcerations and lon-
gitudinal fissures throughout the cecum and terminal ileum with typical
histopathologic features of CD. Prednisolone (1 mg/kg/day) and 5-ASA
(1 g/day) were started. With a worsening clinical examination and radio-
graphic evidence of pneumatosis, he was taken to the operating room for
a right colectomy. Histological examination of the specimen confirmed the
diagnosis of CD. Postoperatively, the patient continued to be febrile and was
pancytopenic with normal folate and vitamin B12 serum levels. He required 51blood transfusions for his anemia. Fanconi’s anemia was ruled out by a neg-
ative diepoxybutane (DEB) test. Hemoglobin electrophoresis showed an in-
creased fetal hemoglobin (5.6%). Bone marrow aspiration at 2 weeks after
initiation of steroids and 5-ASA revealed trilineage dysplasia with a moderate
hypocellularity, and 2% blasts. A peripheral blood smear showed no blasts
at that time. Cytogenetic analysis of the bone marrow revealed chromosome
20 abnormalities (monosomy), chromosome 1 derivative duplication, and
chromosome 8 trisomy in 8 of a total of 9 cells analyzed. These abnormalities
were confirmed by fluorescence in situ hybridization (FISH). The patient
had significant improvement of trilineage cell counts after administration of
granulocyte-colony stimulating factor (G-CSF) (5 µg/kg) daily for 2 weeks 62and was discharged in satisfactory condition.
Over the next 2 years, G-CSF treatments were given at 6, 12, and 18
months for recurrent pancytopenia. Bone marrow biopsy prior to starting
each additional G-CSF treatment showed dyshematopoietic abnormalities
similar to the first bone marrow examination but with 3, 3, and 17% blasts,
respectively. In addition to increased bone marrow blasts, the peripheral
Crohn Disease and Myelodysplastic Syndrome
blood smear showed 7% blasts, suggestive of a diagnosis of refractory ane-
mia with excess blasts in transformation (RAEB-2). At 22 months the pa-
tient progressed to an acute myeloid leukemia, requiring treatment with
chlorodeoxyadenosine and citarabine (one cycle). A bone marrow aspira-
tion performed 2 weeks after completion of treatment showed complete re-
mission. As of this manuscript (at 24 months follow-up), the patient’s disease
MDS is a bone marrow stem-cell disorder characterized primarily by pe-
ripheral cytopenias and hypocellular dysplastic bone marrow, although oc-
casionally it can be found to be associated with hypercellular or normocel-
lular bone marrow. Based on the French–American–British (FAB) classifica-
tion , MDS includes refractory anemia (type I), refractory anemia with
ringed sideroblasts (type II), chronic myelomonocytic leukemia (type III),
refractory anemia with excess blasts (type IV), and refractory anemia with
excess blasts in transformation (type V). More recently, the classification of
the myeloid neoplasms had been refined by the World Health Organization
(WHO), utilizing not only morphologic findings but also all available
information, including genetic, immunophenotypic, biologic, and clinical
features, to define specific disease entities. Because of the lack of specific
data in the previous literature reports, we find it necessary to use the origi-
nal FAB classification. We have included in Table 1, however, our suggested
categorization of these case reports according to the WHO classification.
A total of 21 cases of CD associated with one of five different types of
MDS described above have been reported in the indexed English-language
medical literature [1–9]. In addition, 3 cases of CD in association with other
leukemias apart from the FAB classification have been reported [10, 11].
A pathophysiologic link between CD and MDS has been suggested on
the basis of a common immunologic impairment. It is unknown whether
underlying immunologic alterations account for the development of these
diseases or whether the additional immunosuppressive status caused by one
disease predisposes to the development of the other. In 1992, Eng et al. 
were the first to find chromosome 20 abnormalities in the bone marrow
cells of 3 of the 4 patients with coexistent MDS and CD. Unlike the frequent
occurrence of clonal chromosomal abnormalities in the bone marrow cells of
patients with MDS, karyotypic abnormalities in intestinal cells have not been
seen in patients with CD. The chromosome 20 abnormality is described in
5% of primary MDS in the elderly population . However, since Eng’s
publication, all other reports of patients with coexisting CD and MSD or
CD and leukemia have failed to report that abnormality (except ours) (see
MDS usually develop in patients over 60 years of age. CD is typically 110
diagnosed in younger persons, with a suggested second peak after 60 years. 111In this case, curiously, both conditions were present in a 9-year-old boy, while 112all other reported cases of coexistence of both conditions involved older 113patients (mean age 68 years; range 28–83). Gumruk et al.  described one 114case of pyoderma gangrenosum in a 11-month-old girl with MDS who had 115a normal cytogenetic study of her bone marrow and did not have intestinal 116abnormalities.
MDS/leukemia and CD, these disorders were simultaneously diagnosed 119in 10 other patients in addition to ours (cases 5, 6, 10–14, 16, 17, 21, 25) 120[2, 3, 6, 7, 9]. CD clearly antedated (at least one year) MDS/leukemia 121in 10 patients (cases 7–9, 15, 18–20, 22–24) [3–5, 7, 8, 11, 17], whereas 122MDS antedated those of CD in the remaining 4 patients (1–4) . All 24 123previous cases reported had CD involvement of either colon and/or ileum. 124As for the treatment of CD, most patients received steroids and/or 5-ASA. 125Although cases of acute leukemia have been described in patients receiving 126immunosuppressives with or without corticosteroids, acute leukemia as a 127direct effect of either 5-ASA or prednisone has not been documented.
In the majority of cases, CD was clinically managed. Four patients re- 129
quired an operation because of failure of medical treatment (cases 19–23). 130Specific therapy for MDS/leukemia varied among the 20 patients for whom 131that kind of information was reported. Eleven patients received no specific 132therapy. However, 4 patients with MDS (2 with FAB type IV, and 2 with FAB 133type V), and 3 with non-FAB leukemia required antineoplastic medications. 134Two other patients received synthetic testosterone (Danazol) (Table 1).
Due to the fact that most of these disorders affect mainly the elderly, 136
aggressive treatment is difficult in most cases, leaving only expectant ther- 137apy with supportive measures. In the present report, despite progression to 138myeloid leukemia, the young age of onset may have contributed to a good 139initial response to the chemotherapeutic agents. However, the relative short 140follow-up period after treatment of myeloid leukemia does not allow us to 141make further statements regarding outcome.
In conclusion, although the coexistence of MDS and CD has been ex- 143
clusively reported in adults and elderly, the diagnosis of MDS should also be 144considered in children with CD and persistent peripheral cytopenia. The sig- 145nificance of an association between chromosome 20 abnormalities with the 146development of concomitant conditions (MDS and CD) remains unclear. REFERENCES
 Eng C, Farraye FA, Shulman LN, et al. The association between the myelodysplastic syndromes and 149
Crohn disease. Ann Intern Med. 1992;117:661–662. Crohn Disease and Myelodysplastic Syndrome
 Yoshida C, Kojima H, Ishigaki T, et al. Association of pyoderma gangrenosum and sterile os-
teomyelitis in a patient having myelodysplastic syndrome with der(1;7)(q10;q10). Eur J Haematol.
 Sahay R, Prangnell DR, Scott BB. Inflammatory bowel disease and refractory anaemia (myelodys-
plasia). Gut. 1993;34:1630–1631.
 Castellote J, Porta F, Tuset E, Salinas R. Crohn’s disease and the myelodysplastic syndrome. J ClinGastroenterol. 1997;24:286–287.
 Boberg KM, Brinch L, Vatn M. Crohn disease and the myelodysplastic syndrome. Ann Intern Med.
 Bosch X, Bernadich O, Vera M. The association between Crohn disease and the myelodysplastic
syndromes: report of 3 cases and review of the literature. Medicine (Baltimore). 1998;77:371–377.
 Hebbar M, Kozlowski D, Wattel E, et al. Association between myelodysplastic syndromes and
inflammatory bowel diseases: report of seven new cases and review of the literature. Leukemia.
 Halme L, von Knorring J, Elonen E. Development of acute myelocytic leukemia in patients with
Crohn’s disease. Dig Dis Sci. 1990;35:1553–1556.
 Tani T, Sakai Y, Shirai Y, Ohtake M, Hatakeyama K. Simultaneous development of Crohn’s disease
and myelodysplastic syndrome progressing to acute myelocytic leukemia in a patient with a normal
karyotype. J Gastroenterol. 1996;31:599–602.
 Mir Madjlessi SH, Farmer RG, Weick JK. Inflammatory bowel disease and leukemia: a report of
seven cases of leukemia in ulcerative colitis and Crohn’s disease and review of the literature. DigDis Sci. 1986;31:1025–1031.
 Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med.
 Mitelman F. Catalog of Chromosome Aberrations in Cancer, ed 2. New York: AR Liss; 1985:538.
 Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic
syndromes. Br J Haematol. 1982;51:189–199.
 Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors:Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press;
 Mufti GJ. Chromosomal deletions in the myelodysplastic syndrome. Leuk Res. 1992;16:35–41.
 Gumruk F, Tuncer MA, Hicsonmez G. Pyoderma gangrenosum in a child with myelodysplastic
syndrome. J Pediatr Hematol Oncol. 2000;22:362–364.
 Podolsky DK. Inflammatory bowel disease (1). N Engl J Med. 1991;325:928–937.
Annals of Hepatology 2007; 6(4): October-December: 222-226 Original Article Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions* Ajay Duseja;1 Ashim Das;2 Radha Krishan Dhiman;1 Yogesh Kumar Chawla;1 Kiran K. Thumburu;1 Sanjay Bhadada;3 Anil Abstract same cohort treated only wit
I. INTRODUCTION The named End-Payor plaintiffs seek class certification of a class comprised of individual consumers, third-party payors (“TPPs”), union plan sponsors, and insurance companies that purchased or provided reimbursements for Nexium in those states that permit such an action. See Corrected Consol. Am. Class Action Compl. & Demand Jury Trial (“End-Payors’ Compl.”)